

How we made an impact in 2019

We are passionate about people—the people who make up our company, the nearly 200 million people our medicines reach each day and the people in the communities we serve. This passion underpins our Environmental, Social and Governance (ESG) efforts, sharpening our focus on serving our patients through our quality medicines and programs, supporting the health and well-being of our people, putting protocols in place to ensure compliance and ethical conduct and protecting our planet.

Our Patients

Expanded portfolio of quality medicines worldwide

25

approvals for innovative specialty medicines



1,000+

approvals for generic medicines



\$1B+

invested in research & development



\$246M¹

worth of medicines donated to patients



Launched **resources** for those who support patients, including **tools for pharmacists** and **caregiver programs** in **7 countries**



4

additional clinics selected for Enhancing Access2Care to develop creative strategies to prevent and treat chronic conditions



3

awards for increasing access to medicine, public health leadership in addressing multiple chronic conditions and partnering to deliver essential medicines

Our People



93%

of sites implemented global Environment, Health and Safety Management System

Best-recorded employee safety performance



11%

reduction in total recordable injury rate



23%

improvement in lost time injury rate



4%

improvement in total lost workdays



46%

of management positions held by women



19,200+

employees acknowledged in first year of global recognition program



82%

of employees completed annual survey

Our Protocols



15,000+

employees trained on 8 key ethical behavior topics



4

policies and positions published on Clinical Trial Transparency & Disclosure, Access to Medicines, Animal Welfare and Expanded Access Programs



140

new suppliers under EcoVadis risk mitigation framework, which helps monitor supply chain sustainability

Our Planet



greenhouse gas emissions by

17%

from 2017

Reduced



total waste by

13%

from 2018



total energy consumption by

6%

from 2018

Our Performance

2020 AMR Benchmark from Access to Medicine Foundation

37% improvement from 2018

Sustainalytics

Top 14% of pharmaceutical companies

FTSE4Good

88th percentile for sub-sector

Dow Jones Sustainability Index

55th percentile, compared to 40th in 2017

ISS QualityScore

Highest score for environmental and social performance